First-in-Human Study of a Novel Conformal Pulsed-Field Ablation Balloon Catheter for Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation

Background

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia globally, with an estimated incidence of 1.5-2.0% in the general population. This condition markedly diminishes quality of life, elevates stroke risk fivefold, triples the incidence of congestive heart failure, and is associated with increased overall mortality. These adverse consequences primarily result from rapid, irregular ventricular rates and ineffective atrial contraction, which compromise cardiac output. The ensuing atrial dyssynchrony promotes blood stasis, elevating the risk of thrombus formation and subsequent ischemic stroke. Diagnosis is confirmed by electrocardiographic (ECG) documentation of chaotic atrial electrical activity.

First-line management typically involves pharmacotherapy targeting either ventricular rate control or rhythm control-the restoration and maintenance of sinus rhythm. However, antiarrhythmic drugs are limited by proarrhythmic potential, diminishing long-term efficacy, and possible increased mortality, especially in patients with ventricular dysfunction. Catheter ablation offers superior outcomes, including reduced AF recurrence, fewer cardiovascular hospitalizations, and decreased arrhythmia relapse. Current guidelines recommend ablation for symptomatic, drug-refractory paroxysmal AF, with pulmonary vein isolation (PVI) established as the foundational procedural strategy.

Conventional thermal ablation using radiofrequency or cryoenergy is an established, effective treatment for achieving PVI. However, the non-selective nature of thermal energy carries a risk of collateral damage to adjacent structures, potentially leading to rare but serious complications. Each modality presents specific trade-offs: radiofrequency ablation is technically demanding and time-intensive, while cryoballoon ablation offers ease of use but less precision for ablating non-pulmonary vein targets.

Pulsed field ablation (PFA) utilizes high-voltage, ultra-rapid electrical pulses to induce irreversible electroporation and non-thermal cell death. This energy source demonstrates high cardiomyocyte selectivity, thereby sparing adjacent critical structures such as the esophagus, phrenic nerve, and pulmonary veins. Notably, PFA has not been associated with typical thermal complications like atrioesophageal fistula, phrenic nerve palsy, or pulmonary vein stenosis. By minimizing collateral injury, PFA holds promise for enhancing the safety profile of PVI without compromising efficacy.